Target Validation Information
Target ID T78709
Target Name 5-hydroxytryptamine 1A receptor
Target Type
Successful
Drug Potency against Target 9-Methoxy-1,2,3,4-tetrahydro-anthracen-2-ylamine Drug Info Ki = 2520 nM
Sarizotan Drug Info Ki = 0.1 nM [552412]
2-(4-Methyl-piperazin-1-yl)-4-phenyl-pyrimidine Drug Info Ki = 613 nM
BTS-79018 Drug Info Ki = 3.6 nM [552197]
3-(1-Propyl-pyrrolidin-3-yl)-phenol Drug Info Ki = 201 nM
1-Propyl-3-(3-trifluoromethyl-phenyl)-pyrrolidine Drug Info Ki = 351 nM
N-[4-(4-Phenyl-piperazin-1-yl)-butyl]-benzamide Drug Info Ki = 11 nM [533428]
CGS-12066B Drug Info IC50 = 19 nM [532389]
GR-127935 Drug Info IC50 = 425 nM [525694]
LY-334370 Drug Info Ki = 22 nM [527293]
3-(1,2,3,6-Tetrahydro-pyridin-4-yl)-1H-indole Drug Info IC50 = 140 nM [532389]
WAY-466 Drug Info Ki = 234 nM [527381]
4-(2-(3-chlorophenoxy)phenyl)piperidine Drug Info Ki = 5 nM [530474]
Buspirone Drug Info IC50 = 24 nM [553127]
3-Ethyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-6-ol Drug Info IC50 = 630 nM [526822]
1-(2-Methoxy-phenyl)-piperazine Drug Info Ki = 281 nM [528039]
AR-129330 Drug Info IC50 = 16.9 nM [530396]
Sumanirole Drug Info Ki = 73 nM [534334]
2-(4-Bromo-2-methoxy-phenyl)-1-methyl-ethylamine Drug Info Ki = 2900 nM [533498]
8-Methoxy-2-(4-methyl-piperazin-1-yl)-quinoline Drug Info Ki = 1900 nM [533482]
1-(2-Butoxy-phenyl)-piperazine Drug Info Ki = 19.3 nM [533134]
1-(3-Fluoro-phenyl)-piperazine Drug Info Ki = 86.5 nM [533134]
1-(2-Ethoxy-phenyl)-piperazine Drug Info Ki = 42.6 nM [533134]
1-(2-Chloro-phenyl)-piperazine Drug Info Ki = 226 nM [528039]
CHLOROPHENYLPIPERAZINE Drug Info Ki = 25 nM [533134]
1,6-bis(4-m-tolylpiperazin-1-yl)hexane Drug Info Ki = 48 nM [530927]
4-(2-fluoro-6-phenoxyphenyl)piperidine Drug Info Ki = 128 nM [530474]
1-Ethyl-4-(2-methoxy-phenyl)-piperazine Drug Info Ki = 203 nM [533873]
1-(2-(benzyloxy)phenyl)piperazine Drug Info Ki = 28 nM [530474]
4-(2-(4-fluorobenzyloxy)phenyl)piperidine Drug Info Ki = 77 nM [530474]
3-(4-Benzyl-piperidin-1-ylmethyl)-chromen-4-one Drug Info Ki = 120 nM [527368]
4-(2-(benzyloxy)-6-fluorophenyl)piperidine Drug Info Ki = 364 nM [530474]
1-[(3-methoxybenzyl)oxy]-2-(2-phenylethyl)benzene Drug Info Ki = 5000 nM [528493]
1-(2,5-Dimethoxy-phenyl)-piperazine Drug Info Ki = 1035 nM [533476]
1-(benzyloxy)-2-[2-(3-methoxyphenyl)ethyl]benzene Drug Info Ki = 5000 nM [528493]
1-(2-(2-chlorophenoxy)pyridin-3-yl)piperazine Drug Info Ki = 4.5 nM [530596]
PHENYLPIPERAZINE Drug Info Ki = 135 nM [533482]
4-Benzyl-1-chroman-3-ylmethyl-piperidine Drug Info Ki = 226 nM [527368]
UH-232 Drug Info Ki = 168 nM
2-(4-Bromo-phenyl)-1-methyl-ethylamine Drug Info Ki = 2830 nM [533498]
4-(2-fluoro-6-(4-fluorophenoxy)phenyl)piperidine Drug Info Ki = 156 nM [530474]
2-(2-methoxyphenoxy)-3-(piperidin-4-yl)pyridine Drug Info Ki = 92 nM [530596]
3-Butyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-6-ol Drug Info IC50 = 420 nM [526822]
3-(2-Amino-propyl)-1H-indol-5-ol Drug Info IC50 = 19.6 nM [526713]
1-(7-Methoxy-naphthalen-2-yl)-piperazine Drug Info Ki = 2.8 nM [534528]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Drug Info Ki = 280 nM [531079]
(R)-(-)-10-methyl-11-hydroxyaporphine Drug Info Ki = 216 nM [528876]
3-Naphthalen-1-yl-pyrrolidine Drug Info Ki = 95 nM
TERTATOLOL Drug Info Ki = 18.2 nM
2-Dipropylamino-1,2,3,4-tetrahydro-anthracen-9-ol Drug Info Ki = 2520 nM
8-Methoxy-1,2,3,4-tetrahydro-naphthalen-2-ylamine Drug Info Ki = 158 nM
3-{[2-(2-phenylethyl)phenoxy]methyl}pyridine Drug Info Ki = 5000 nM [528493]
2-{[2-(2-phenylethyl)phenoxy]methyl}pyridine Drug Info Ki = 5000 nM [528493]
PB-28 Drug Info Ki = 28.6 nM [534094]
3-Naphthalen-1-yl-1-propyl-pyrrolidine Drug Info Ki = 73 nM
SB-656104 Drug Info Ki = 562 nM [527395]
5-chloro-4-methyl-3,4-dihydroquinazolin-2-amine Drug Info Ki = 192 nM [529148]
4-Benzyl-1-chroman-2-ylmethyl-piperidine Drug Info Ki = 11.5 nM [527368]
1,6-bis(4-(pyridin-2-yl)piperazin-1-yl)hexane Drug Info Ki = 16 nM [530927]
LYSERGIC ACID DIETHYLAMIDE Drug Info Ki = 5.1 nM [533701]
Flibanserin Drug Info Ki = 1 nM
2-(5-Methoxy-1H-indol-3-yl)-1-methyl-ethylamine Drug Info IC50 = 86.4 nM [526713]
SLV-313 Drug Info Ki = 0.79 nM [552595]
MCL-516 Drug Info Ki = 151 nM [529541]
2-(3-Bromophenylthio)-N,N-dimethylethanamine Drug Info Ki = 676 nM [530699]
2-(Biphenyl-3-ylthio)-N,N-dimethylethanamine Drug Info Ki = 516 nM [530699]
1-(2,5-Dimethoxy-4-methyl-phenyl)-piperazine Drug Info Ki = 680 nM [533476]
1-Naphthalen-2-yl-piperazine Drug Info Ki = 265 nM [533482]
1-(2-Fluoro-phenyl)-piperazine Drug Info Ki = 57.9 nM [533134]
2-Piperazin-1-yl-benzonitrile Drug Info Ki = 26.1 nM [533134]
1-(3-Nitro-phenyl)-piperazine Drug Info Ki = 250 nM [533134]
8-Methoxy-quinolin-2-ylamine Drug Info Ki = 10400 nM [533482]
1-(2,5-dimethoxyphenyl)propan-2-amine Drug Info Ki = 1020 nM [533498]
2-(2-Methoxy-phenyl)-1-methyl-ethylamine Drug Info Ki = 3500 nM [533498]
(3-Chloro-phenyl)-piperazin-1-yl-methanone Drug Info Ki = 17100 nM [533476]
5-chloro-4-ethyl-3,4-dihydroquinazolin-2-amine Drug Info Ki = 1081 nM [529148]
1,2,3,4-Tetrahydro-naphthalen-2-ylamine Drug Info Ki = 380 nM [533482]
2-(2-Amino-propyl)-5-bromo-4-methoxy-phenol Drug Info Ki = 1710 nM [533498]
QUIPAZINE Drug Info Ki = 1584 nM [530451]
SEROTONIN Drug Info Ki = 1.6 nM [530451]
2-(4-Benzyl-piperidin-1-ylmethyl)-chroman-4-one Drug Info Ki = 297 nM [527368]
2-(3-Methoxy-phenyl)-1-methyl-ethylamine Drug Info Ki = 2660 nM [533498]
TIOSPIRONE Drug Info IC50 = 2.85 nM [528304]
3-(3-Methanesulfonyl-phenyl)-1-propyl-pyrrolidine Drug Info Ki = 807 nM
N-methyllaurotetanine Drug Info Ki = 85 nM [528095]
(R)-2,11-Diaminoaporphine Drug Info Ki = 2300 nM [529541]
(R)-11-Amino-2-methoxyaporphine Drug Info Ki = 640 nM [529541]
ESCHOLTZINE Drug Info Ki = 6000 nM [528095]
2-Piperazin-1-yl-phenol Drug Info Ki = 150 nM [533476]
4-(2-(benzyloxy)-3-fluorophenyl)piperidine Drug Info Ki = 606 nM [530474]
4-(2-(3-fluorophenoxy)phenyl)piperidine Drug Info Ki = 11 nM [530474]
1-(2-phenoxyphenyl)piperazine Drug Info Ki = 128 nM [530474]
4-(3-fluoro-2-phenoxyphenyl)piperidine Drug Info Ki = 20 nM [530474]
1-(2-(phenoxymethyl)phenyl)piperazine Drug Info Ki = 189 nM [530474]
1-(2-(2-fluorobenzyloxy)phenyl)piperazine Drug Info Ki = 31 nM [530474]
8-methoxy-4-methyl-3,4-dihydroquinazolin-2-amine Drug Info Ki = 32 nM [529148]
5-chloro-3,4-dihydroquinazolin-2-amine Drug Info Ki = 1701 nM [529148]
1-(benzyloxy)-2-(2-phenylethyl)benzene Drug Info Ki = 5000 nM [528493]
1-Benzyl-4-chroman-2-ylmethyl-piperazine Drug Info Ki = 20.7 nM [527368]
2-(2-fluorophenoxy)-3-(piperidin-4-yl)pyridine Drug Info Ki = 13 nM [530596]
4-(2-fluoro-6-(3-fluorophenoxy)phenyl)piperidine Drug Info Ki = 21 nM [530474]
3-(piperidin-4-yl)-2-(o-tolyloxy)pyridine Drug Info Ki = 60 nM [530596]
3-(2-Benzylamino-ethoxy)-phenol Drug Info Ki = 1782 nM [534787]
4-(2-(2-fluoro-5-methylphenoxy)phenyl)piperidine Drug Info Ki = 57 nM [530474]
N-(3-(1H-indol-4-yloxy)propyl)cyclohexanamine Drug Info Ki = 78.4 nM [529018]
5,6-dichloro-3,4-dihydroquinazolin-2-amine Drug Info Ki = 1080 nM [529148]
2-(2-chlorophenoxy)-3-(piperidin-4-yl)pyridine Drug Info Ki = 16 nM [530596]
4-(2-phenoxyphenyl)piperidine Drug Info Ki = 63 nM [530474]
1-(2-Isopropoxy-phenyl)-piperazine Drug Info Ki = 19 nM [533134]
WB-4101 Drug Info Ki = 2.68 nM [533936]
SPIPERONE Drug Info Ki = 602 nM [533936]
4-(1H-indol-4-yloxy)-1-(isopropylamino)butan-2-ol Drug Info Ki = 1772 nM [529018]
1,6-bis(4-phenylpiperazin-1-yl)hexane Drug Info Ki = 3 nM [530927]
4-(2-(4-fluorophenoxy)phenyl)piperidine Drug Info Ki = 117 nM [530474]
1-(2-(4-fluorophenoxy)phenyl)piperazine Drug Info Ki = 8 nM [530474]
4-(2-(benzyloxy)phenyl)piperidine Drug Info Ki = 121 nM [530474]
Adatanserin Drug Info Ki = 1 nM [534942]
1-(2-(3-fluorophenoxy)phenyl)piperazine Drug Info Ki = 9 nM [530474]
2-phenoxy-3-(piperidin-4-yl)pyridine Drug Info Ki = 101 nM [530596]
4-(2-fluoro-6-(2-fluorophenoxy)phenyl)piperidine Drug Info Ki = 4.6 nM [530596]
1-(2-((3-fluorophenoxy)methyl)phenyl)piperazine Drug Info Ki = 116 nM [530474]
1-Butyl-4-(2-methoxy-phenyl)-piperazine Drug Info Ki = 57 nM [533873]
UH-301 Drug Info Ki = 52 nM [534363]
Sunepitron Drug Info Ki = 92 nM [528210]
PD-158771 Drug Info Ki = 2.6 nM [552219]
BMY-7378 Drug Info Ki = 8.2 nM [534142]
4-(2-(2-fluorobenzyloxy)phenyl)piperidine Drug Info Ki = 47 nM [530474]
PG-01037 Drug Info Ki = 85.4 nM [528974]
3-(4-Benzyl-piperidin-1-ylmethyl)-chroman-4-one Drug Info Ki = 260 nM [527368]
SB-271046 Drug Info Ki = 340 nM [529191]
MAZAPERTINE Drug Info Ki = 1.7 nM [533800]
1-(2-methoxyphenyl)-4-pentylpiperazine Drug Info Ki = 5.16 nM [531189]
CP-293019 Drug Info IC50 = 180 nM [534783]
OPC-14523 Drug Info IC50 = 2.3 nM [552279]
N-(3-(1H-indol-4-yloxy)propyl)cyclopentanamine Drug Info Ki = 233 nM [529018]
A-80426 Drug Info Ki = 2 nM [527799]
1-Methyl-1,3-dihydro-indol-2-one Drug Info Ki = 29 nM [526055]
SNAP-8719 Drug Info Ki = 300 nM [527512]
Etisulergine Drug Info IC50 = 26 nM [533501]
1-(2-Methoxy-phenyl)-4-propyl-piperazine Drug Info Ki = 249 nM [533873]
1-Naphthalen-1-yl-piperazine Drug Info Ki = 5 nM [533482]
3-Amino-1-(2-amino-5-methoxy-phenyl)-propan-1-one Drug Info Ki = 345 nM [533476]
1-(4-Bromo-2,5-dimethoxy-phenyl)-piperazine Drug Info Ki = 820 nM [533476]
1,6-bis(4-(3-chlorophenyl)piperazin-1-yl)hexane Drug Info Ki = 16 nM [530927]
BP-897 Drug Info Ki = 4.9 nM [526696]
SSR-181507 Drug Info Ki = 0.242 nM [552362]
8-Methoxy-2-piperazin-1-yl-quinoline Drug Info Ki = 415 nM [533482]
1,6-bis(4-(3-methoxyphenyl)piperazin-1-yl)hexane Drug Info Ki = 8 nM [530927]
Brolamfetamine Drug Info Ki = 3340 nM [533498]
2-(2'-methyl-biphenyl-3-yl)-ethylamine Drug Info Ki = 1470 nM [528780]
1-(3-Trifluoromethyl-phenyl)-piperazine Drug Info Ki = 20 nM [533476]
RWJ-25730 Drug Info Ki = 3.3 nM [533800]
Bifeprunox Drug Info Ki = 64.6 nM [552493]
N-Benzyl-4-(2-diphenyl)-1-piperazinehexanamide Drug Info Ki = 161 nM [529703]
AGROCLAVINE Drug Info IC50 = 140 nM [532683]
1-((S)-2-aminopropyl)-1H-indazol-6-ol Drug Info Ki = 141 nM [527952]
Vilazodone Drug Info IC50 = 0.2 nM [552853]
1192U90 Drug Info Ki = 3.8 nM [553241]
3-Phenyl-1-propyl-pyrrolidine Drug Info Ki = 453 nM
References
Ref 552412Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profile. J Neural Transm (Vienna). 2004 Feb;111(2):113-26. Epub 2003 Dec 31.
Ref 552197N-Substituted (2,3-dihydro-1,4-benzodioxin-2-yl)methylamine derivatives as D(2) antagonists/5-HT(1A) partial agonists with potential as atypical antipsychotic agents. J Med Chem. 1999 Aug 26;42(17):3342-55.
Ref 533428J Med Chem. 1988 Oct;31(10):1968-71.Arylpiperazine derivatives as high-affinity 5-HT1A serotonin ligands.
Ref 532389J Med Chem. 1990 Aug;33(8):2087-93.3-(1,2,5,6-Tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one: a potent and selective serotonin (5-HT1B) agonist and rotationally restricted phenolic analogue of 5-methoxy-3-(1,2,5,6-tetrahydropyrid-4-yl)indole.
Ref 525694J Med Chem. 2000 Feb 10;43(3):517-25.New selective and potent 5-HT(1B/1D) antagonists: chemistry and pharmacological evaluation of N-piperazinylphenyl biphenylcarboxamides and biphenylsulfonamides.
Ref 527293Bioorg Med Chem Lett. 2004 Dec 20;14(24):6011-6.Design, synthesis and evaluation of bicyclic benzamides as novel 5-HT1F receptor agonists.
Ref 532389J Med Chem. 1990 Aug;33(8):2087-93.3-(1,2,5,6-Tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one: a potent and selective serotonin (5-HT1B) agonist and rotationally restricted phenolic analogue of 5-methoxy-3-(1,2,5,6-tetrahydropyrid-4-yl)indole.
Ref 527381J Med Chem. 2005 Jan 27;48(2):353-6.Discovery of 5-arylsulfonamido-3-(pyrrolidin-2-ylmethyl)-1H-indole derivatives as potent, selective 5-HT6 receptor agonists and antagonists.
Ref 530474Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. Epub 2009 Oct 12.Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.
Ref 553127Selective interaction of novel anxiolytics with 5-hydroxytryptamine1A receptors. Biol Psychiatry. 1985 Sep;20(9):971-9.
Ref 526822J Med Chem. 1992 Oct 30;35(22):3984-90.6-Hydroxy-3-n-propyl-2,3,4,5-tetrahydro-1H-3-benzazepine and analogs: new centrally acting 5-HT1A receptor agonists.
Ref 528039J Med Chem. 1991 Jun;34(6):1850-4.Pyrimido[5,4-b]indole derivatives. 1. A new class of potent and selective alpha 1 adrenoceptor ligands.
Ref 530396Bioorg Med Chem Lett. 2009 Nov 1;19(21):6166-71. Epub 2009 Sep 6.Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: in vitro profiling and in vivo evaluation.
Ref 534334J Med Chem. 1997 Feb 28;40(5):639-46.Synthesis and biological activities of (R)-5,6-dihydro-N,N-dimethyl-4H-imidazo[4,5,1-ij]quinolin-5-amine and its metabolites.
Ref 533498J Med Chem. 1986 Feb;29(2):194-9.5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues.
Ref 533482J Med Chem. 1986 Nov;29(11):2375-80.5-HT1 and 5-HT2 binding characteristics of some quipazine analogues.
Ref 533134J Med Chem. 1989 May;32(5):1052-6.Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy.
Ref 533134J Med Chem. 1989 May;32(5):1052-6.Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy.
Ref 533134J Med Chem. 1989 May;32(5):1052-6.Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy.
Ref 528039J Med Chem. 1991 Jun;34(6):1850-4.Pyrimido[5,4-b]indole derivatives. 1. A new class of potent and selective alpha 1 adrenoceptor ligands.
Ref 533134J Med Chem. 1989 May;32(5):1052-6.Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy.
Ref 530927J Med Chem. 2010 Jun 24;53(12):4803-7.Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors.
Ref 530474Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. Epub 2009 Oct 12.Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.
Ref 533873J Med Chem. 1994 Aug 19;37(17):2754-60.Structure-activity relationship studies of central nervous system agents. 13. 4-[3-(Benzotriazol-1-yl)propyl]-1-(2-methoxyphenyl)piperazine, a new putative 5-HT1A receptor antagonist, and its analogs.
Ref 530474Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. Epub 2009 Oct 12.Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.
Ref 530474Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. Epub 2009 Oct 12.Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.
Ref 527368J Med Chem. 2005 Jan 13;48(1):266-73.Synthesis and structure-activity relationships of 1-aralkyl-4-benzylpiperidine and 1-aralkyl-4-benzylpiperazine derivatives as potent sigma ligands.
Ref 530474Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. Epub 2009 Oct 12.Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.
Ref 528493J Med Chem. 2006 Nov 2;49(22):6607-13.Arylmethyloxyphenyl derivatives: small molecules displaying P-glycoprotein inhibition.
Ref 533476J Med Chem. 1986 May;29(5):630-4.Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents.
Ref 528493J Med Chem. 2006 Nov 2;49(22):6607-13.Arylmethyloxyphenyl derivatives: small molecules displaying P-glycoprotein inhibition.
Ref 530596Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7. Epub 2009 Dec 6.Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agonists.
Ref 533482J Med Chem. 1986 Nov;29(11):2375-80.5-HT1 and 5-HT2 binding characteristics of some quipazine analogues.
Ref 527368J Med Chem. 2005 Jan 13;48(1):266-73.Synthesis and structure-activity relationships of 1-aralkyl-4-benzylpiperidine and 1-aralkyl-4-benzylpiperazine derivatives as potent sigma ligands.
Ref 533498J Med Chem. 1986 Feb;29(2):194-9.5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues.
Ref 530474Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. Epub 2009 Oct 12.Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.
Ref 530596Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7. Epub 2009 Dec 6.Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agonists.
Ref 526822J Med Chem. 1992 Oct 30;35(22):3984-90.6-Hydroxy-3-n-propyl-2,3,4,5-tetrahydro-1H-3-benzazepine and analogs: new centrally acting 5-HT1A receptor agonists.
Ref 526713J Med Chem. 2003 Sep 11;46(19):4188-95.A novel and selective 5-HT2 receptor agonist with ocular hypotensive activity: (S)-(+)-1-(2-aminopropyl)-8,9-dihydropyrano[3,2-e]indole.
Ref 534528J Med Chem. 1997 Nov 21;40(24):3974-8.5-HT1B receptor antagonist properties of novel arylpiperazide derivatives of 1-naphthylpiperazine.
Ref 531079J Med Chem. 2010 Sep 9;53(17):6386-97.Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential.
Ref 528876Bioorg Med Chem Lett. 2007 Aug 1;17(15):4128-30. Epub 2007 May 23.R-(-)-N-alkyl-11-hydroxy-10-hydroxymethyl- and 10-methyl-aporphines as 5-HT1A receptor ligands.
Ref 528493J Med Chem. 2006 Nov 2;49(22):6607-13.Arylmethyloxyphenyl derivatives: small molecules displaying P-glycoprotein inhibition.
Ref 528493J Med Chem. 2006 Nov 2;49(22):6607-13.Arylmethyloxyphenyl derivatives: small molecules displaying P-glycoprotein inhibition.
Ref 534094J Med Chem. 1996 Jan 5;39(1):176-82.New sigma and 5-HT1A receptor ligands: omega-(tetralin-1-yl)-n-alkylamine derivatives.
Ref 527395Bioorg Med Chem Lett. 2005 Feb 1;15(3):747-50.Novel 3-aminochromans as potential pharmacological tools for the serotonin 5-HT(7) receptor.
Ref 529148Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61. Epub 2007 Oct 30.Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation.
Ref 527368J Med Chem. 2005 Jan 13;48(1):266-73.Synthesis and structure-activity relationships of 1-aralkyl-4-benzylpiperidine and 1-aralkyl-4-benzylpiperazine derivatives as potent sigma ligands.
Ref 530927J Med Chem. 2010 Jun 24;53(12):4803-7.Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors.
Ref 533701J Med Chem. 1995 Mar 17;38(6):958-66.Stereoselective LSD-like activity in a series of d-lysergic acid amides of (R)- and (S)-2-aminoalkanes.
Ref 526713J Med Chem. 2003 Sep 11;46(19):4188-95.A novel and selective 5-HT2 receptor agonist with ocular hypotensive activity: (S)-(+)-1-(2-aminopropyl)-8,9-dihydropyrano[3,2-e]indole.
Ref 552595SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug. Neuropsychopharmacology. 2007 Jan;32(1):78-94. Epub 2006 May 17.
Ref 529541Bioorg Med Chem. 2008 Jul 15;16(14):6675-81. Epub 2008 Jun 5.Synthesis and pharmacological investigation of novel 2-aminothiazole-privileged aporphines.
Ref 530699Bioorg Med Chem. 2010 Mar 1;18(5):1958-67. Epub 2010 Jan 18.SAR studies on new bis-aryls 5-HT7 ligands: Synthesis and molecular modeling.
Ref 530699Bioorg Med Chem. 2010 Mar 1;18(5):1958-67. Epub 2010 Jan 18.SAR studies on new bis-aryls 5-HT7 ligands: Synthesis and molecular modeling.
Ref 533476J Med Chem. 1986 May;29(5):630-4.Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents.
Ref 533482J Med Chem. 1986 Nov;29(11):2375-80.5-HT1 and 5-HT2 binding characteristics of some quipazine analogues.
Ref 533134J Med Chem. 1989 May;32(5):1052-6.Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy.
Ref 533134J Med Chem. 1989 May;32(5):1052-6.Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy.
Ref 533134J Med Chem. 1989 May;32(5):1052-6.Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy.
Ref 533482J Med Chem. 1986 Nov;29(11):2375-80.5-HT1 and 5-HT2 binding characteristics of some quipazine analogues.
Ref 533498J Med Chem. 1986 Feb;29(2):194-9.5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues.
Ref 533498J Med Chem. 1986 Feb;29(2):194-9.5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues.
Ref 533476J Med Chem. 1986 May;29(5):630-4.Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents.
Ref 529148Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61. Epub 2007 Oct 30.Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation.
Ref 533482J Med Chem. 1986 Nov;29(11):2375-80.5-HT1 and 5-HT2 binding characteristics of some quipazine analogues.
Ref 533498J Med Chem. 1986 Feb;29(2):194-9.5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues.
Ref 530451J Med Chem. 2009 Nov 12;52(21):6946-50.Novel, potent, and selective quinoxaline-based 5-HT(3) receptor ligands. 1. Further structure-activity relationships and pharmacological characterization.
Ref 530451J Med Chem. 2009 Nov 12;52(21):6946-50.Novel, potent, and selective quinoxaline-based 5-HT(3) receptor ligands. 1. Further structure-activity relationships and pharmacological characterization.
Ref 527368J Med Chem. 2005 Jan 13;48(1):266-73.Synthesis and structure-activity relationships of 1-aralkyl-4-benzylpiperidine and 1-aralkyl-4-benzylpiperazine derivatives as potent sigma ligands.
Ref 533498J Med Chem. 1986 Feb;29(2):194-9.5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues.
Ref 528304J Med Chem. 1991 Nov;34(11):3316-28.Synthesis and biological activity of the putative metabolites of the atypical antipsychotic agent tiospirone.
Ref 528095J Nat Prod. 2006 Mar;69(3):432-5.Alkaloids from Eschscholzia californica and their capacity to inhibit binding of [3H]8-Hydroxy-2-(di-N-propylamino)tetralin to 5-HT1A receptors in Vitro.
Ref 529541Bioorg Med Chem. 2008 Jul 15;16(14):6675-81. Epub 2008 Jun 5.Synthesis and pharmacological investigation of novel 2-aminothiazole-privileged aporphines.
Ref 529541Bioorg Med Chem. 2008 Jul 15;16(14):6675-81. Epub 2008 Jun 5.Synthesis and pharmacological investigation of novel 2-aminothiazole-privileged aporphines.
Ref 528095J Nat Prod. 2006 Mar;69(3):432-5.Alkaloids from Eschscholzia californica and their capacity to inhibit binding of [3H]8-Hydroxy-2-(di-N-propylamino)tetralin to 5-HT1A receptors in Vitro.
Ref 533476J Med Chem. 1986 May;29(5):630-4.Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents.
Ref 530474Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. Epub 2009 Oct 12.Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.
Ref 530474Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. Epub 2009 Oct 12.Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.
Ref 530474Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. Epub 2009 Oct 12.Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.
Ref 530474Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. Epub 2009 Oct 12.Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.
Ref 530474Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. Epub 2009 Oct 12.Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.
Ref 530474Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. Epub 2009 Oct 12.Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.
Ref 529148Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61. Epub 2007 Oct 30.Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation.
Ref 529148Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61. Epub 2007 Oct 30.Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation.
Ref 528493J Med Chem. 2006 Nov 2;49(22):6607-13.Arylmethyloxyphenyl derivatives: small molecules displaying P-glycoprotein inhibition.
Ref 527368J Med Chem. 2005 Jan 13;48(1):266-73.Synthesis and structure-activity relationships of 1-aralkyl-4-benzylpiperidine and 1-aralkyl-4-benzylpiperazine derivatives as potent sigma ligands.
Ref 530596Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7. Epub 2009 Dec 6.Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agonists.
Ref 530474Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. Epub 2009 Oct 12.Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.
Ref 530596Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7. Epub 2009 Dec 6.Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agonists.
Ref 534787Bioorg Med Chem Lett. 1998 Feb 3;8(3):295-300.New generation dopaminergic agents. 2. Discovery of 3-OH-phenoxyethylamine and 3-OH-N1-phenylpiperazine dopaminergic templates.
Ref 530474Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. Epub 2009 Oct 12.Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.
Ref 529018Bioorg Med Chem Lett. 2007 Oct 15;17(20):5600-4. Epub 2007 Aug 22.Indoloxypropanolamine analogues as 5-HT(1A) receptor antagonists.
Ref 529148Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61. Epub 2007 Oct 30.Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation.
Ref 530596Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7. Epub 2009 Dec 6.Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agonists.
Ref 530474Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. Epub 2009 Oct 12.Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.
Ref 533134J Med Chem. 1989 May;32(5):1052-6.Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy.
Ref 533936J Med Chem. 1993 Oct 15;36(21):3161-5.Synthesis of (R,S)-trans-8-hydroxy-2-[N-n-propyl-N-(3'-iodo-2'-propenyl)amino]tetral in (trans-8-OH-PIPAT): a new 5-HT1A receptor ligand.
Ref 533936J Med Chem. 1993 Oct 15;36(21):3161-5.Synthesis of (R,S)-trans-8-hydroxy-2-[N-n-propyl-N-(3'-iodo-2'-propenyl)amino]tetral in (trans-8-OH-PIPAT): a new 5-HT1A receptor ligand.
Ref 529018Bioorg Med Chem Lett. 2007 Oct 15;17(20):5600-4. Epub 2007 Aug 22.Indoloxypropanolamine analogues as 5-HT(1A) receptor antagonists.
Ref 530927J Med Chem. 2010 Jun 24;53(12):4803-7.Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors.
Ref 530474Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. Epub 2009 Oct 12.Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.
Ref 530474Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. Epub 2009 Oct 12.Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.
Ref 530474Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. Epub 2009 Oct 12.Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.
Ref 534942Synthesis and SAR of adatanserin: novel adamantyl aryl- and heteroarylpiperazines with dual serotonin 5-HT(1A) and 5-HT(2) activity as potential anxiolytic and antidepressant agents. J Med Chem. 1999Dec 16;42(25):5077-94.
Ref 530474Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. Epub 2009 Oct 12.Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.
Ref 530596Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7. Epub 2009 Dec 6.Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agonists.
Ref 530596Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7. Epub 2009 Dec 6.Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agonists.
Ref 530474Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. Epub 2009 Oct 12.Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.
Ref 533873J Med Chem. 1994 Aug 19;37(17):2754-60.Structure-activity relationship studies of central nervous system agents. 13. 4-[3-(Benzotriazol-1-yl)propyl]-1-(2-methoxyphenyl)piperazine, a new putative 5-HT1A receptor antagonist, and its analogs.
Ref 534363J Med Chem. 1997 Apr 11;40(8):1252-7.N-[2-[(substituted chroman-8-yl)oxy]ethyl]-4-(4-methoxyphenyl)butylamines: synthesis and wide range of antagonism at the human 5-HT1A receptor.
Ref 528210J Med Chem. 2006 Jun 1;49(11):3116-35.An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.
Ref 552219PD 158771, a potential antipsychotic agent with D(2)/D(3) partial agonist and 5-HT(1A) agonist actions. I. Neurochemical effects. Neuropharmacology. 2000 Apr 27;39(7):1197-210.
Ref 534142J Med Chem. 1996 Mar 1;39(5):1125-9.8-[4-[2-(1,2,3,4-Tetrahydroisoquinolinyl]butyl-8-azaspiro[4.5]decane-7,9-dione: a new 5-HT1A receptor ligand with the same activity profile as buspirone.
Ref 530474Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. Epub 2009 Oct 12.Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.
Ref 528974J Med Chem. 2007 Aug 23;50(17):4135-46. Epub 2007 Aug 2.Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agents.
Ref 527368J Med Chem. 2005 Jan 13;48(1):266-73.Synthesis and structure-activity relationships of 1-aralkyl-4-benzylpiperidine and 1-aralkyl-4-benzylpiperazine derivatives as potent sigma ligands.
Ref 529191Bioorg Med Chem Lett. 2008 Jan 15;18(2):738-43. Epub 2007 Nov 17.Discovery of 3-aryl-3-methyl-1H-quinoline-2,4-diones as a new class of selective 5-HT6 receptor antagonists.
Ref 533800J Med Chem. 1994 Apr 15;37(8):1060-2.A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects.
Ref 531189Bioorg Med Chem Lett. 2010 Nov 15;20(22):6628-32. Epub 2010 Sep 21.Identification of a red-emitting fluorescent ligand for in vitro visualization of human serotonin 5-HT(1A) receptors.
Ref 534783Bioorg Med Chem Lett. 1998 Apr 7;8(7):725-30.Synthesis, SAR and pharmacology of CP-293,019: a potent, selective dopamine D4 receptor antagonist.
Ref 552279Antidepressant-like responses to the combined sigma and 5-HT1A receptor agonist OPC-14523. Neuropharmacology. 2001 Dec;41(8):976-88.
Ref 529018Bioorg Med Chem Lett. 2007 Oct 15;17(20):5600-4. Epub 2007 Aug 22.Indoloxypropanolamine analogues as 5-HT(1A) receptor antagonists.
Ref 527799J Med Chem. 2005 Oct 20;48(21):6523-43.Designed multiple ligands. An emerging drug discovery paradigm.
Ref 526055Bioorg Med Chem Lett. 2001 May 7;11(9):1229-31.Influence of the terminal amide fragment geometry in some 3-arylideneindolin-2(1H)-ones on their 5-HT1A/5-HT2A receptor activity.
Ref 527512J Med Chem. 2005 Apr 21;48(8):3076-9.Synthesis and structure-activity relationship of fluoro analogues of 8-{2-[4-(4-methoxyphenyl)piperazin-1yl]ethyl}-8-azaspiro[4.5]decane-7,9-dione as selective alpha(1d)-adrenergic receptor antagonists.
Ref 533501J Med Chem. 1985 Oct;28(10):1540-2.Resolution and absolute configuration of the potent dopamine agonist N,N-diethyl-N'-[(3 alpha, 4a alpha, 10a beta)-1,2,3,4,4a,5,10,10a- -octahydro-6-hydroxy-1-propyl-3-benzo[g]quinolinyl]sulfamide.
Ref 533873J Med Chem. 1994 Aug 19;37(17):2754-60.Structure-activity relationship studies of central nervous system agents. 13. 4-[3-(Benzotriazol-1-yl)propyl]-1-(2-methoxyphenyl)piperazine, a new putative 5-HT1A receptor antagonist, and its analogs.
Ref 533482J Med Chem. 1986 Nov;29(11):2375-80.5-HT1 and 5-HT2 binding characteristics of some quipazine analogues.
Ref 533476J Med Chem. 1986 May;29(5):630-4.Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents.
Ref 533476J Med Chem. 1986 May;29(5):630-4.Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents.
Ref 530927J Med Chem. 2010 Jun 24;53(12):4803-7.Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors.
Ref 526696J Med Chem. 2003 Aug 28;46(18):3822-39.Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors.
Ref 552362SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist. I: Neurochemical and electrophysiological profile. Neuropsychopharmacology. 2003 Dec;28(12):2064-76.
Ref 533482J Med Chem. 1986 Nov;29(11):2375-80.5-HT1 and 5-HT2 binding characteristics of some quipazine analogues.
Ref 530927J Med Chem. 2010 Jun 24;53(12):4803-7.Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors.
Ref 533498J Med Chem. 1986 Feb;29(2):194-9.5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues.
Ref 528780Bioorg Med Chem Lett. 2007 Jun 1;17(11):3018-22. Epub 2007 Mar 23.Novel aminoethylbiphenyls as 5-HT7 receptor ligands.
Ref 533476J Med Chem. 1986 May;29(5):630-4.Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents.
Ref 533800J Med Chem. 1994 Apr 15;37(8):1060-2.A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects.
Ref 552493Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. Int J Neuropsychopharmacol. 2005 Sep;8(3):341-56. Epub 2005 Feb 11.
Ref 529703J Med Chem. 2008 Sep 25;51(18):5813-22.Structural modifications of N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides: influence on lipophilicity and 5-HT7 receptor activity. Part III.
Ref 532683J Med Chem. 1988 Aug;31(8):1512-9.Ergolines as selective 5-HT1 agonists.
Ref 527952J Med Chem. 2006 Jan 12;49(1):318-28.1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity.
Ref 5528535-HT1 receptor augmentation strategies as enhanced efficacy: therapeutics for psychiatric disorders. Curr Top Med Chem. 2008;8(12):1008-23.
Ref 553241Synthesis and evaluation of heterocyclic carboxamides as potential antipsychotic agents. J Med Chem. 1996 Nov 22;39(24):4692-703.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.